ASH 2022 Conference Coverage

 

ASH 2022 Conference Coverage
A

ASH 2022 Outcomes of Patients With Accelerated/Blast-Phase MPNs in the Current Era of Myeloid Therapies

By ASH 2022 Conference Coverage FEATURING Anand Patel
By ASH 2022 Conference Coverage FEATURING Anand Patel
107 views
January 3, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Featured Video

15:43
Incyte

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal
MDS and MPN
18:24

Ropeginterferon Alfa-2b vs. Standard Therapy for Low-Risk Pts With P…

ASH 2022 Conference Coverage

T. Barbui

181 views
05:09

MEDALIST Study: Multiple Episodes of Transfusion Independence With L…

ASH 2022 Conference Coverage

U. Platzbecker

191 views
31:13

Selected Updates in MDS

ASH 2022 Conference Coverage

A. Zeidan

486 views
08:24

Phase 2 FIGHT-203 Study: Pemigatinib in Pts With Myeloid/Lymphoid Ne…

ASH 2022 Conference Coverage

A. Vannucchi

436 views
09:27

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

ASH 2022 Conference Coverage

M. McMullin

1.1K views
03:41

ASH 2022: Venetoclax Combined With Cladribine, Idarubicin, Cytarabin…

ASH 2022 Conference Coverage

G. Borthakur

175 views
06:04

ASH 2022 Real-World Validation of Molecular International Prognostic…

ASH 2022 Conference Coverage

M. Della Porta

49 views
11:00

ASH 2022: Management of Accelerated and Blast-Phase MPN

ASH 2022 Conference Coverage

R. Rampal

57 views
10:14

ASH 2022: Navitoclax and Ruxolitinib in JAKi-Naïve Patients With MF …

ASH 2022 Conference Coverage

F. Passamonti

77 views
27:09

ASH 2022: What Is Complete HLA Match in 2022?

ASH 2022 Conference Coverage

S. Spellman

191 views
06:34

ASH 2022 Outcomes of Patients With Accelerated/Blast-Phase MPNs in t…

ASH 2022 Conference Coverage

A. Patel

107 views
09:54

ASH 2022 Phase II Study of Myeloablative 8/8- or 7/8-Matched AlloSCT…

ASH 2022 Conference Coverage

A. Hoover

28 views
06:06

Synergistic Activity of Luspatercept and Erythroid Stimulating Agent…

ASH 2022 Conference Coverage

R. Komrokji

280 views
06:55

Luspatercept for Treatment of LR-MDS: Real World Data Replicates MED…

ASH 2022 Conference Coverage

R. Komrokji

334 views
07:02

ASH 2022 Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-…

ASH 2022 Conference Coverage

D. Sallman

40 views
10:30

ASH 2022 Primary Results of STIMULUS-MDS1: A Randomized, Double-Blin…

ASH 2022 Conference Coverage

A. Zeidan

131 views
06:10

Phase 3b, Single-Arm, Multicenter Study to Assess the Efficacy, Safe…

ASH 2022 Conference Coverage

J. Mascarenhas

134 views
08:11

Validation of 2022 WHO & ICC Classifications in MDS - An Analysis on…

ASH 2022 Conference Coverage

S. Ball

191 views
08:02

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…

ASH 2022 Conference Coverage

S. Holtan

350 views
11:40

ASH 2022 Efficacy & Safety of Add-On Parsaclisib to Ruxolitinib Ther…

ASH 2022 Conference Coverage

A. Yacoub

57 views
08:57

ASH 2022 Impact of Allelic State on Overall Survival in TP53-Mutant …

ASH 2022 Conference Coverage

J. Bewersdorf

92 views
11:20

Updated Results From the Momentum Phase 3 Study of Momelotinib vs. D…

ASH 2022 Conference Coverage

A. Gerds

231 views